ACADIA Pharmaceuticals Inc.
ACAD
$21.72
-$0.08-0.37%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -5.61% | 1.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.61% | 1.92% | |||
| Cost of Revenue | -8.40% | 1.38% | |||
| Gross Profit | -3.82% | 2.28% | |||
| SG&A Expenses | 9.90% | 16.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.28% | 9.77% | |||
| Operating Income | -126.54% | -51.36% | |||
| Income Before Tax | -84.87% | -40.98% | |||
| Income Tax Expenses | 100.14% | -809.54% | |||
| Earnings from Continuing Operations | -98.67% | 281.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -98.67% | 281.13% | |||
| EBIT | -126.54% | -51.36% | |||
| EBITDA | -107.99% | -47.51% | |||
| EPS Basic | -98.68% | 280.03% | |||
| Normalized Basic EPS | -84.96% | -41.19% | |||
| EPS Diluted | -98.75% | 280.83% | |||
| Normalized Diluted EPS | -85.00% | -41.21% | |||
| Average Basic Shares Outstanding | 0.70% | 0.30% | |||
| Average Diluted Shares Outstanding | 0.79% | 0.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||